Sgroi, Dennis C.
Treuner, Kai
Zhang, Yi
Piper, Tammy
Salunga, Ranelle
Ahmed, Ikhlaaq
Doos, Lucy
Thornber, Sarah
Taylor, Karen J.
Brachtel, Elena
Pirrie, Sarah
Schnabel, Catherine A.
Rea, Daniel
Bartlett, John M. S.
Article History
Received: 24 August 2022
Accepted: 7 December 2022
First Online: 16 December 2022
Declarations
:
: The University of Birmingham Cancer Research UK Clinical Trial Unit (CRCTU) was the sponsoring institution and secured ethical and regulatory approvals from the UK Research Ethics Committee (REC, reference 16/EM/0142), Health Research Authority (HRA), Confidentiality Advisory Group (CAG) and from the PBPP in Scotland, and also carried out final biomarker data integration with the aTTom clinical database.
: DCS, YZ, and CAS are named inventors on a patent to use HOXB13/IL17BR and Molecular Grade Index assays to predict breast cancer outcome. K Treuner, YZ, and RCS are employees of Biotheranostics, A Hologic Company and shareholders of Hologic and prior shareholders of Biotheranostics, Inc., currently a subsidiary of Hologic Inc. CAS is a former employee of Biotheranostics, A Hologic Company and prior shareholder of Biotheranostics, Inc., currently a subsidiary of Hologic, Inc. EFB is a consultant for Philips Healthcare and receives research funding from Biotheranostics, A Hologic Company. DWR receives honoraria from Genomic Health, Novartis, Pfizer, Roche, and research funding from Biotheranostics, A Hologic Company, Celgene, and Roche. JMSB receives or has received honoraria from NanoString Technologies, Inc., Oncology Education, Biotheranostics, A Hologic Company, and MedcomXchange, Communications Inc. He is a consultant/advisor for Insight Genetics, Inc., BioNTech AG, Biotheranostics, A Hologic Company, Pfizer, Rna Diagnostics Inc., oncoXchange/MedcomXchange Communications Inc., Herbert Smith French Solicitors, and OncoCyte Corporation and receives travel support from Biotheranostics, A Hologic Company, NanoString Technologies, Inc., and Breast Cancer Society of Canada. He receives research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies, Inc., Stratifyer GmbH, Biotheranostics, A Hologic Company. All remaining authors, TP, IA, LD, ST and SJP, have declared no conflicts of interest.